The place of bone-marrow transplantation in acute myelogenous leukaemia
28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a s...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1980-05, Vol.1 (8177), p.1047-1050 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1050 |
|---|---|
| container_issue | 8177 |
| container_start_page | 1047 |
| container_title | The Lancet (British edition) |
| container_volume | 1 |
| creator | Powles, R L Morgenstern, G Clink, H M Hedley, D Bandini, G Lumley, H Watson, J G Lawson, D Spence, D Barrett, A Jameson, B Lawler, S Kay, H E McElwain, T J |
| description | 28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a simultaneously treated group of 22 patients in first remission who received sibling bone-marrow transplants after cyclophosphamide (60 mg/kg) given for 2 days and followed by a single dose of 1000 rads total body irradiation. Substantially fewer transplanted patients (4 out of 22) than chemo-immunotherapy patients (19 out of 28) relapsed (p less than 0.005) and 14 (64%) transplanted patients remain alive, well, and disease-free. Survival curves of the two groups of patients show that the transplanted patients never fared worse than the chemo-immunotherapy patients. We suggest that when possible young AML patients in remission should be offered transplantation as an alternative form of treatment. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_75107739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75107739</sourcerecordid><originalsourceid>FETCH-LOGICAL-p138t-f9eaa27e48b1ae92e2b79174941ecf3e8c275d01b323f401010bb1344b25b3303</originalsourceid><addsrcrecordid>eNotjzFPwzAUhD2ASin8BCRPbJGe_Zw4HlEFBalSlzJHdvoCgcQOsSPUf48lqhtuuE-nuyu2BqGgqDRWN-w2xi8AUBWUK7aqBCAaWLPd8ZP4NNiWeOi4C56K0c5z-OVptj7mxCeb-uB577ltl0R8PNMQPsiHJfKBlm9LY2_v2HVnh0j3F9-w95fn4_a12B92b9unfTEJrFPRGbJWalK1E5aMJOm0EVoZJajtkOpW6vIEwqHEToHIck6gUk6WDhFwwx7_e6c5_CwUUzP2saUh76Q8qNGlAK3RZPDhAi5upFMzzX0-dm4uz_EP1rtTlw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75107739</pqid></control><display><type>article</type><title>The place of bone-marrow transplantation in acute myelogenous leukaemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Powles, R L ; Morgenstern, G ; Clink, H M ; Hedley, D ; Bandini, G ; Lumley, H ; Watson, J G ; Lawson, D ; Spence, D ; Barrett, A ; Jameson, B ; Lawler, S ; Kay, H E ; McElwain, T J</creator><creatorcontrib>Powles, R L ; Morgenstern, G ; Clink, H M ; Hedley, D ; Bandini, G ; Lumley, H ; Watson, J G ; Lawson, D ; Spence, D ; Barrett, A ; Jameson, B ; Lawler, S ; Kay, H E ; McElwain, T J</creatorcontrib><description>28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a simultaneously treated group of 22 patients in first remission who received sibling bone-marrow transplants after cyclophosphamide (60 mg/kg) given for 2 days and followed by a single dose of 1000 rads total body irradiation. Substantially fewer transplanted patients (4 out of 22) than chemo-immunotherapy patients (19 out of 28) relapsed (p less than 0.005) and 14 (64%) transplanted patients remain alive, well, and disease-free. Survival curves of the two groups of patients show that the transplanted patients never fared worse than the chemo-immunotherapy patients. We suggest that when possible young AML patients in remission should be offered transplantation as an alternative form of treatment.</description><identifier>ISSN: 0140-6736</identifier><identifier>PMID: 6103390</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Age Factors ; Bone Marrow Transplantation ; Child ; Child, Preschool ; Female ; Humans ; Immunotherapy ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - therapy ; Male ; Middle Aged ; Transplantation, Isogeneic</subject><ispartof>The Lancet (British edition), 1980-05, Vol.1 (8177), p.1047-1050</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6103390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Powles, R L</creatorcontrib><creatorcontrib>Morgenstern, G</creatorcontrib><creatorcontrib>Clink, H M</creatorcontrib><creatorcontrib>Hedley, D</creatorcontrib><creatorcontrib>Bandini, G</creatorcontrib><creatorcontrib>Lumley, H</creatorcontrib><creatorcontrib>Watson, J G</creatorcontrib><creatorcontrib>Lawson, D</creatorcontrib><creatorcontrib>Spence, D</creatorcontrib><creatorcontrib>Barrett, A</creatorcontrib><creatorcontrib>Jameson, B</creatorcontrib><creatorcontrib>Lawler, S</creatorcontrib><creatorcontrib>Kay, H E</creatorcontrib><creatorcontrib>McElwain, T J</creatorcontrib><title>The place of bone-marrow transplantation in acute myelogenous leukaemia</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a simultaneously treated group of 22 patients in first remission who received sibling bone-marrow transplants after cyclophosphamide (60 mg/kg) given for 2 days and followed by a single dose of 1000 rads total body irradiation. Substantially fewer transplanted patients (4 out of 22) than chemo-immunotherapy patients (19 out of 28) relapsed (p less than 0.005) and 14 (64%) transplanted patients remain alive, well, and disease-free. Survival curves of the two groups of patients show that the transplanted patients never fared worse than the chemo-immunotherapy patients. We suggest that when possible young AML patients in remission should be offered transplantation as an alternative form of treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Bone Marrow Transplantation</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Transplantation, Isogeneic</subject><issn>0140-6736</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotjzFPwzAUhD2ASin8BCRPbJGe_Zw4HlEFBalSlzJHdvoCgcQOsSPUf48lqhtuuE-nuyu2BqGgqDRWN-w2xi8AUBWUK7aqBCAaWLPd8ZP4NNiWeOi4C56K0c5z-OVptj7mxCeb-uB577ltl0R8PNMQPsiHJfKBlm9LY2_v2HVnh0j3F9-w95fn4_a12B92b9unfTEJrFPRGbJWalK1E5aMJOm0EVoZJajtkOpW6vIEwqHEToHIck6gUk6WDhFwwx7_e6c5_CwUUzP2saUh76Q8qNGlAK3RZPDhAi5upFMzzX0-dm4uz_EP1rtTlw</recordid><startdate>19800517</startdate><enddate>19800517</enddate><creator>Powles, R L</creator><creator>Morgenstern, G</creator><creator>Clink, H M</creator><creator>Hedley, D</creator><creator>Bandini, G</creator><creator>Lumley, H</creator><creator>Watson, J G</creator><creator>Lawson, D</creator><creator>Spence, D</creator><creator>Barrett, A</creator><creator>Jameson, B</creator><creator>Lawler, S</creator><creator>Kay, H E</creator><creator>McElwain, T J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19800517</creationdate><title>The place of bone-marrow transplantation in acute myelogenous leukaemia</title><author>Powles, R L ; Morgenstern, G ; Clink, H M ; Hedley, D ; Bandini, G ; Lumley, H ; Watson, J G ; Lawson, D ; Spence, D ; Barrett, A ; Jameson, B ; Lawler, S ; Kay, H E ; McElwain, T J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p138t-f9eaa27e48b1ae92e2b79174941ecf3e8c275d01b323f401010bb1344b25b3303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Bone Marrow Transplantation</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Transplantation, Isogeneic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Powles, R L</creatorcontrib><creatorcontrib>Morgenstern, G</creatorcontrib><creatorcontrib>Clink, H M</creatorcontrib><creatorcontrib>Hedley, D</creatorcontrib><creatorcontrib>Bandini, G</creatorcontrib><creatorcontrib>Lumley, H</creatorcontrib><creatorcontrib>Watson, J G</creatorcontrib><creatorcontrib>Lawson, D</creatorcontrib><creatorcontrib>Spence, D</creatorcontrib><creatorcontrib>Barrett, A</creatorcontrib><creatorcontrib>Jameson, B</creatorcontrib><creatorcontrib>Lawler, S</creatorcontrib><creatorcontrib>Kay, H E</creatorcontrib><creatorcontrib>McElwain, T J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Powles, R L</au><au>Morgenstern, G</au><au>Clink, H M</au><au>Hedley, D</au><au>Bandini, G</au><au>Lumley, H</au><au>Watson, J G</au><au>Lawson, D</au><au>Spence, D</au><au>Barrett, A</au><au>Jameson, B</au><au>Lawler, S</au><au>Kay, H E</au><au>McElwain, T J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The place of bone-marrow transplantation in acute myelogenous leukaemia</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1980-05-17</date><risdate>1980</risdate><volume>1</volume><issue>8177</issue><spage>1047</spage><epage>1050</epage><pages>1047-1050</pages><issn>0140-6736</issn><abstract>28 patients with acute myeloid leukaemia (AML) in first remission were maintained on chemotherapy, consisting of courses of cytosine arabinoside and daunorubicin, and immunotherapy with irradiated AML cells and BCG. The relapse rate and survival rate of these patients were compared with those of a simultaneously treated group of 22 patients in first remission who received sibling bone-marrow transplants after cyclophosphamide (60 mg/kg) given for 2 days and followed by a single dose of 1000 rads total body irradiation. Substantially fewer transplanted patients (4 out of 22) than chemo-immunotherapy patients (19 out of 28) relapsed (p less than 0.005) and 14 (64%) transplanted patients remain alive, well, and disease-free. Survival curves of the two groups of patients show that the transplanted patients never fared worse than the chemo-immunotherapy patients. We suggest that when possible young AML patients in remission should be offered transplantation as an alternative form of treatment.</abstract><cop>England</cop><pmid>6103390</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1980-05, Vol.1 (8177), p.1047-1050 |
| issn | 0140-6736 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75107739 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Age Factors Bone Marrow Transplantation Child Child, Preschool Female Humans Immunotherapy Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - therapy Male Middle Aged Transplantation, Isogeneic |
| title | The place of bone-marrow transplantation in acute myelogenous leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A15%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20place%20of%20bone-marrow%20transplantation%20in%20acute%20myelogenous%20leukaemia&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Powles,%20R%20L&rft.date=1980-05-17&rft.volume=1&rft.issue=8177&rft.spage=1047&rft.epage=1050&rft.pages=1047-1050&rft.issn=0140-6736&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E75107739%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75107739&rft_id=info:pmid/6103390&rfr_iscdi=true |